跳至主要内容
临床试验/NCT04047784
NCT04047784Enrolling By Invitation不适用

Pilot Study to Evaluate the Role of Endobronchial Ultrasound (EBUS) in the Diagnosis of Acute Pulmonary Embolism in Critically Ill Patients

University of California, Los Angeles4 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2019年8月12日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
Enrolling By Invitation
入组人数
60
试验地点
4
主要终点
Assess sensitivity and specificity of EBUS to visualize or exclude PE by its ability to identify a clot.

研究概览

简要总结

Acute pulmonary embolism (PE) in critically ill patients is common and often life threatening. The diagnosis of acute PE is often entertained in intensive care unit patients who develop unexplained hypotension or hypoxemia. Obtaining diagnostic confirmation of acute PE with a contrast-enhanced computed tomography of the chest (CT angiogram) may be difficult as patients are often too unstable for transport to the CT scanner or have renal insufficiency limiting the ability to receive intravenous contrast agents. Making or excluding the diagnosis of acute PE in these patients is critically important, as hemodynamic instability or right heart dysfunction, if due to PE, puts patients in the massive or submassive category and increased mortality risk. More aggressive therapies such as thrombolysis, extracorporeal membrane oxygenation or surgical embolectomy are often entertained. The investigators have previously described a case where endobronchial ultrasound (EBUS) was employed in the diagnostic algorithm of suspected acute PE and significantly affected treatment recommendations. The investigators believe that, in these patients, use of EBUS to assess for thrombotic occlusion of the central pulmonary vasculature can fill a critical gap in the decision tree for management of these patients.

EBUS has become part of the diagnostic approach in a number of clinical situations, including the workup and staging of suspected malignancy, unexplained lymphadenopathy, and diagnosis of mediastinal and parabronchial masses. There is strong evidence that EBUS is equivalent to mediastinoscopy in the mediastinal staging of lung cancer. The number of physicians skilled and experienced in performance of EBUS has increased dramatically, and training in the procedure is frequently obtained in a pulmonary fellowship.

To our knowledge, there have been no prospective studies that investigate the use of EBUS as a tool for the diagnosis of acute central pulmonary embolism in critically ill patients where obtaining diagnostic confirmation of this diagnosis with a contrast-enhanced computed tomography of the chest is not safe or feasible.

详细描述

This is a single center, pilot study to evaluate critically ill patients diagnosed with acute pulmonary embolism using endobronchial ultrasound (EBUS). The investigators anticipate to enroll 20 subjects at Ronald Reagan UCLA Medical Center and UCLA Medical Center, Santa Monica. The enrolled subjects will be imaged using the flexible bronchoscopy with EBUS.

After informed consent is obtained, the following procedure will be performed:

An Olympus EBUS bronchoscope will be used for all endobronchial ultrasound examinations. This scope has a 6.9 mm outer diameter, a 2.7 mm working channel and 30-degree oblique forward-viewing optics. A 12 MHz linear ultrasound transducer with a maximum penetration of 50 mm will be linked to a processor (Olympus EU-ME2) that allows an integrated power Doppler mode to visualize the vascular blood flow.

Bronchoscopy will be introduced through the adaptor connected to the endotracheal tube, in patients who are already under general anesthesia and on mechanical ventilation. The bronchoscope will be advanced into the airways and endobronchial ultrasound of the main pulmonary artery (PA) and lobar branches will be performed in a standardized fashion as follow:

Advance the bronchoscopy into the right main bronchus distally to the level of the right lower lobe, between 12 and 3 o'clock position where the interlobar artery of the PA is seen. Then the scope will be pulled back slowly, turning counterclockwise, following the course of the PA on the medial wall of the right bronchial tree until the level of the carina, where the right main PA and the PA trunk are seen. The scope is then turned to the right again, towards 3 o'clock following the right upper lobe bronchus to examine the upper lobar artery. The scope is then advanced into the left main bronchus, towards 9 o'clock to examine the upper lobar artery, then advanced distally to the left lower lobe bronchus to examine the interlobar artery. At the completion of the imaging the EBUS bronchoscope will be withdrawn.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient ≥ 18 years of age.
  • The patient or patient's surrogate must understand and sign informed consent form (ICF).
  • Intubated patients in the intensive care unit (ICU) where there is a clinical concern for acute pulmonary embolism or a confirmed diagnosis for acute pulmonary embolism.

排除标准

  • Patient does not meet the requirements to undergo clinical bronchoscopy, as determined by the treating physician.
  • Endotracheal tube size less than 8.0 mm.
  • Contraindications to lidocaine.
  • Pulmonary Vascular Mapping Substudy:
  • Enrollment for the pulmonary vascular mapping substudy will be based on the following inclusion and exclusion criteria:
  • Inclusion criteria:
  • Patient ≥ 18 years of age.
  • The patient or patient's surrogate must understand and sign informed consent form (ICF).
  • Intubated patients undergoing clinical bronchoscopy, as determined by the treating physician.
  • Exclusion criteria:
  • Patient does not meet the requirements to undergo clinical bronchoscopy, as determined by the treating physician.
  • Endotracheal tube size less than 8.0 mm.
  • Contraindications to lidocaine.
  • Retrospective Chart Review:
  • Of the 60 total subjects enrolled in the study, media including images and videos that are previously recorded for 20 patients who underwent a clinical bronchoscopy with EBUS as a part of their standard of care will also be available to our research team without consent from the patient to help supplement the data we obtain from the 20 subjects that are enrolled in the pulmonary vascular mapping substudy.

研究组 & 干预措施

Critically Ill Patients

Experimental

Intubated patients in the intensive care unit (ICU) where there is a clinical concern for acute pulmonary embolism or a confirmed diagnosis for acute pulmonary embolism.

The enrolled subjects will be imaged using the flexible bronchoscopy with EBUS.

干预措施: Endobronchial ultrasound (EBUS) (Device)

Patients undergoing standard of care clinical bronchoscopy

Experimental

Patients undergoing clinical bronchoscopy as a part of their standard of care.

The enrolled subjects will be imaged using the flexible bronchoscopy with EBUS.

干预措施: Endobronchial ultrasound (EBUS) (Device)

Previously recorded patient media from standard of care clinical bronchoscopy with EBUS

No Intervention

Patients who underwent a standard of care clinical bronchoscopy with EBUS previously.

Information and media including images and videos that were previously recorded for patients who underwent a standard of care clinical bronchoscopy with EBUS will be available to the study team.

结局指标

主要结局

Assess sensitivity and specificity of EBUS to visualize or exclude PE by its ability to identify a clot.

时间窗: 2 years

Ability for EBUS will be reported by its ability to identify a clot and reporting the location of the clot as: * Main Pulmonary Artery (MPA) * Right Pulmonary Artery (RPA) * Truncus Anterior (TA) or Ascending Branch * Right Interlobar Artery or Descending Branch * Right Basal Trunk * Left Pulmonary Artery (LPA) * Left Interlobar Artery * Left Basal Trunk * Other

Assess sensitivity and specificity of EBUS to visualize or exclude PE by its ability to identify flow around clot(s) present.

时间窗: 2 years

Ability for EBUS will be reported by its ability to identify flow around clot(s) present and reporting the location of the flow around clot(s) present as: * Main Pulmonary Artery (MPA) * Right Pulmonary Artery (RPA) * Truncus Anterior (TA) or Ascending Branch * Right Interlobar Artery or Descending Branch * Right Basal Trunk * Left Pulmonary Artery (LPA) * Left Interlobar Artery * Left Basal Trunk * Other

Patient outcome

时间窗: 2 years

For patients who are unable to have a CT, the investigators will not be able to determine true efficacy, but follow these patients for outcome and subsequent definitive diagnosis of venous thromboembolism. Subsequent patient outcome will be reported as: * Alive * Extended hospitalization * Intervention to prevent impairment or damage * Life-threatening condition * Disability * Death

Assess sensitivity and specificity of EBUS to visualize or exclude PE compared to the chest CT.

时间窗: 2 years

Ability for EBUS will be reported by its ability to identify each major branch and reporting what branched not identified as: * Main Pulmonary Artery (MPA) * Right Pulmonary Artery (RPA) * Truncus Anterior (TA) or Ascending Branch * Right Interlobar Artery or Descending Branch * Right Basal Trunk * Left Pulmonary Artery (LPA) * Left Interlobar Artery * Left Basal Trunk * Other

CT angiogram results (if obtained)

时间窗: 2 years

For patients who have had a chest CT for suspected PE, the investigators will obtain a copy of the participant's chest CT for suspected PE report.

Report any complications

时间窗: 2 years

Complications during or after the procedure will be reported as: * Airway Bleeding * Airway Injury * Hypotension as defined by \< 65 mmHg or need to escalate vasopressors * Hypoxia as defined by \< 90% * Other * None

Patient treatment

时间窗: 2 years

For patients who are unable to have a CT, the investigators will not be able to determine true efficacy, but will report the number of positive and negative studies. Patient treatment will be reported as: * Catheter Directed Lysis * Heparin Drip * Surgical Embolectomy * Thrombolysis * No Treatment for Pulmonary Embolism (PE)

次要结局

  • Other airway finding(s)(2 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Colleen Channick, MD

Clinical Professor of Medicine

University of California, Los Angeles

研究点 (4)

Loading locations...

相似试验